Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ATRA Stock News and Mentions of Atara Biotherapeutics, Inc. Stocktwits
Updated: April 29, 2024 (10:08)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Atara Biotherapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Atara Biotherapeutics, Inc. (ATRA).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Atara Biotherapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Atara Biotherapeutics, Inc. (ATRA)
April 26, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Puma Biotechnology ( PBYI ) in Q1 Earnings?
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
In Article Trend: Neutral
April 5, 2024 (06:44) / "Stocknews.com" (by Defense World Staff)
Atara Biotherapeutics ( NASDAQ:ATRA ) Upgraded at StockNews.com
Atara Biotherapeutics ( NASDAQ:ATRA - Get Free Report ) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Friday. Shares of NASDAQ ATRA opened at $0.78 on Friday.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Atara Biotherapeutics ( ATRA ) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 28, 2024 (06:22) / "Stocknews.com" (by Defense World Staff)
Atara Biotherapeutics ( NASDAQ:ATRA ) Downgraded by StockNews.com
Atara Biotherapeutics ( NASDAQ:ATRA - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday. NASDAQ:ATRA opened at $0.70 on Thursday.
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:06) / "Stocknews.com" (by Defense World Staff)
StockNews.com Lowers Atara Biotherapeutics ( NASDAQ:ATRA ) to Sell
StockNews.com downgraded shares of Atara Biotherapeutics ( NASDAQ:ATRA - Free Report ) from a hold rating to a sell rating in a report published on Monday. NASDAQ:ATRA opened at $0.60 on Monday. The stock's fifty day moving average is $0.74 and its two-hundred day moving average is $0.94.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:27) / "Investor Ideas"
Watching Biotech & Life Science Stocks: ( Nasdaq: IXHL ) ( Nasdaq: ATRA ) ( ASX: CHM ) ( Nasdaq: IMRX )
Watching Biotech & Life Science Stocks: ( Nasdaq: IXHL ) ( Nasdaq: ATRA ) ( ASX: CHM ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (21:07) / "PR Newswire" (by Inc.)
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initiated clinical trial of Phase 1 P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T program
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Pacific Biosciences of California, Inc. (PACB)
Clover Health Investments, Corp. (CLOV)
Fate Therapeutics, Inc. (FATE)
SmileDirectClub, Inc. (SDC)
BridgeBio Pharma, Inc. (BBIO)
Abbott Laboratories (ABT)
Teva Pharmaceutical Industries Lim. (TEVA) (TEVA)
Adagio Therapeutics, Inc. (ADGI)
BiondVax Pharmaceuticals Ltd. (BVXV)
Bright Health Group, Inc. (BHG)
This website uses cookies to ensure you get the best experience on our website